None listed
Conditions
Interventions
This prospective randomised controlled study has been designed to compare analgesia and side-effects of continuous femoral nerve block, spinal morphine and both combined. All patients will receive a spinal anaesthetic with 15-20mgs of bupiviacaine. Patients allocated to the continuous femoral nerve block group will have a femoral nerve block establised using a arrow StimuCath Continuous Nerve Block Kit and ropivacaine 0.75% with adrenaline 5mcg/ml. Patients who are allocated to the spinal morphine group or combination group will have 175mcg preservative-free morphine added to their spinal anaesthestic. Postoperatively, patients who have a continuous femoral nerve block will have an infusion of ropivacaine 0.2% commenced at 12mls per hour until the morning of postoperative day 2. All patient will have an intravenous patient controlled analgesia (PCA) infusion of morphine commenced on 1mg boluses with a lockout period of 7 minutes until the morning of postoperative day 2.
Sponsors
Study design
Eligibility
Inclusion criteria
First time total knee joint replacement.
Exclusion criteria
Inability to understand PCA or VAS scores. Contraindication to spinal anaesthesia (eg. coagulopathy, moderate to severe aortic stenosis, skin infection over insertion site). Contraindication to femoral nerve block (eg. previous valscular surgery in the groin, infection over insertion site, inablity to palpate femoral artery). Contraindiction to spinal and IV morphine (eg. obsructive sleep apnoea). Allergy to study drugs. Containdication to COX-2 inhibitors (eg. renal impairment, ischaemic heart disease). Chronic pain.